These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

667 related items for PubMed ID: 18302519

  • 21. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [Abstract] [Full Text] [Related]

  • 22. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM, Lima N, Knobel M, Cavaliere H, Medeiros-Neto G.
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [Abstract] [Full Text] [Related]

  • 23. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA, Cho SW, Choi HS, Moon S, Moon JH, Kim KW, Park DJ, Yi KH, Park YJ, Cho BY.
    Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
    [Abstract] [Full Text] [Related]

  • 24. Spontaneous hypothyroidism in the follow up of Graves hyperthyroid patients treated with antithyroid drugs.
    De Moraes AV, Pedro AB, Romaldini JH.
    South Med J; 2006 Oct; 99(10):1068-72. PubMed ID: 17100026
    [Abstract] [Full Text] [Related]

  • 25. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T.
    N Engl J Med; 1991 Apr 04; 324(14):947-53. PubMed ID: 1900575
    [Abstract] [Full Text] [Related]

  • 26. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M, Koizumi Y, Aizawa T, Yamada T, Takahashi Y, Watanabe T, Kamoi K.
    J Clin Endocrinol Metab; 1988 Jan 04; 66(1):103-8. PubMed ID: 3121661
    [Abstract] [Full Text] [Related]

  • 27. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K, Amino N, Kubota S, Sasaki I, Nishihara E, Kudo T, Ito M, Fukata S, Miyauchi A.
    Clin Endocrinol (Oxf); 2010 Jun 04; 72(6):845-50. PubMed ID: 19912243
    [Abstract] [Full Text] [Related]

  • 28. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
    Komiya I, Yamada T, Sato A, Kouki T, Nishimori T, Takasu N.
    J Clin Endocrinol Metab; 2001 Aug 04; 86(8):3540-4. PubMed ID: 11502776
    [Abstract] [Full Text] [Related]

  • 29. Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease.
    Kim KW, Park YJ, Kim TY, Park DJ, Park KS, Cho BY.
    Thyroid; 2007 Dec 04; 17(12):1229-34. PubMed ID: 17949264
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy.
    Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, Castellano M, Rosei EA, Chiovato L.
    J Clin Endocrinol Metab; 2008 Oct 04; 93(10):3985-8. PubMed ID: 18664537
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Remission of Graves' hyperthyroidism treated with methimazole.
    Bolaños F, González-Ortiz M, Durón H, Sánchez C.
    Rev Invest Clin; 2002 Oct 04; 54(4):307-10. PubMed ID: 12415954
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Rosei EA.
    Endocr J; 2007 Dec 04; 54(5):713-20. PubMed ID: 17675761
    [Abstract] [Full Text] [Related]

  • 37. Neutropenia Occurs More Often Under Carbimazole than Under Methimazole Treatment in Pediatric Graves' Disease Patients.
    Schempp V, Cebeci AN, Reinauer C, Woelfle J, Dörr HG, Roosen MT, Gohlke J, Gohlke B.
    Thyroid; 2024 Jun 04; 34(6):735-743. PubMed ID: 38613811
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
    Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, Salerno M, Delvecchio M, Peroni E, Pistorio A, Corrias A.
    J Pediatr; 2014 May 04; 164(5):1189-1194.e1. PubMed ID: 24518168
    [Abstract] [Full Text] [Related]

  • 40. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
    Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E.
    J Clin Endocrinol Metab; 2010 Jan 04; 95(1):201-8. PubMed ID: 19906789
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.